Article

GSK Reports Positive Findings for COPD Treatment Studies

Author(s):

Two head-to-head trials comparing the safety of Incruse Ellipta to 2 available bronchodilator treatments used by patients with chronic obstructive pulmonary disease has yielded positive results for GlaxoSmithKline's therapy.

Two head-to-head trials comparing the safety of Incruse Ellipta (umeclidinium) to 2 available bronchodilator treatments used by patients with chronic obstructive pulmonary disease (COPD) has yielded positive results for GlaxoSmithKline’s therapy.

In 12-week multi-center, randomized, blinded study of 1259 patients, the once-daily 62.5 mcg dose of umeclidinium achieved a statistically significant improvement in lung function as 12 weeks compared to a once-daily 18 mcg dose of tiotropium.

The second study was a 12-week multi-center, non-US, randomized, open-label study, which found that the once-daily 62.5 mcg dose of umeclidinium was non-inferior to a once-daily 44 mcg dose of glycopyrronium.

The most common side effects for all 3 treatments were headache and nasopharyngitis.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
4 experts in this video
4 experts in this video
Dr Caroline Vovan
1 expert is featured in this series.
1 expert is featured in this series.
Dr María Díez Campelo
Dr Caroline Vovan
Guy Young, MD
Dr Hans Lee
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo